Patients with HIV with Burkitt's lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era [15]

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 8132-8133

  Spina, Michele ^a   Simonelli, Cecilia ^a   Talamini, Renato ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; RITUXIMAB;

BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; LETTER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; B CELL LYMPHOMA; COMPARATIVE STUDY; MORTALITY; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKITT LYMPHOMA; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE-CELL, DIFFUSE; TREATMENT OUTCOME;

EID: 32944463346     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.9561     Document Type: Letter

References (2)

1. Lim ST, Karim R, Nathwani BN, et al: AIDS-Related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy. J Clin Oncol 23:4430-4438, 2005
2. Spina M, Sparano JA, Jaeger U, et al: Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide (R-CDE) in HIV-associated non-Hodgkin's lymphoma: Pooled results from three phase II trials. Blood 105:1891-1897, 2005